Skip to Main Content

Biogen CEO Michel Vounatsos acknowledged Monday that the company was “wrong” to price its Alzheimer’s disease treatment Aduhelm at $56,000 a year, but added that its decision to later slash the cost nearly in half was “courageous.”

Speaking virtually at the J.P. Morgan Healthcare Conference, Vounatsos described the company’s flagging revenue and the disastrous launch of Aduhem as “near-term challenges [that] are not defining Biogen,” and stressed “the company’s fundamentals are very strong.”


Vounatsos did not address last month’s surprise departure of Al Sandrock, Biogen’s longtime chief scientist. Biogen has previously described Sandrock’s departure as a retirement, but company insiders told STAT that Vounatsos forced Sandrock’s exit, blaming him for the Aduhelm debacle.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.